semaglutide overdose Associated With Reduced Risk of Opioid in Patients With Type 2 Diabetes, Opioid Use Disorder Popular weight-loss drugs like Ozempic

Canadas certificate of supplementary protection register lists semaglutide with patent 2601784, a March 20, 2026 patent expiry date and a CSP term that would have extended to March 20, 2028

Physical activity and exercise for weight loss and maintenance in people living with obesity

Best Pract Res Clin Endocrinol Metab 23(4):443452

No established mechanism exists for GLP-1 receptor agonists to directly cause muscle damage or toxicity

Research on GLP-1 receptor agonists shows that the central nervous system effects extend beyond appetite suppression

GLP-1 responses to absolute exercise load The combined nonlinear interaction between GLP treatment and exercise load was highly significant for both HR and HRV, while exercise alone was not